University of Zurich
Rämistrasse 71, Zürich, Zurich, 8006, Switzerland
Overview
University of Zurich is a higher education institute that offers a wide variety of Master’s, Bachelor’s, and Ph.D. programs. The company also specializes in the fields of clinical medicine, immunology, neuroscience, and structural biology as well as in economics. It also brings benefits to both the private and the public sectors. It makes findings from cutting-edge research available to the public in accessible and engaging lecture series and panel discussions. In addition, the University of Zurich providing a dynamic education based on critical thinking and interdisciplinary exposure. The university is committed to being an internationally significant research university, with graduate, undergraduate, and professional programs of excellent quality. University of Zurich was founded on April 29, 1833, and is headquartered in Zurich, Switzerland.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Education
- Higher Education
- Universities
Investment portfolio
- MUVON Therapeutics
Participated · Series A · May 2021
Muvon Therapeutics is developing an autologous cell therapy using patients' own muscle precursor cells (MPCs) to regenerate damaged sphincter and other skeletal muscle tissue, with electromagnetic stimulation supporting regeneration. The company's lead program targets stress urinary incontinence (SUI), initially focused on women, and is positioned as a minimally invasive, low‑risk therapy that uses no foreign materials. Preclinical work at the University of Zurich over 12 years showed nearly 90% recovery of original muscle strength six months after injection. Muvon began first‑in‑human studies (first patient treated March 2020) and the phase 1 study is proceeding toward finalization, with final results expected this autumn. The startup is a University of Zurich spin‑off, currently employs seven people, and has joined the Wyss Zurich incubator to support clinical development. Planned next steps include completing clinical studies and scaling up production by automating the manufacturing cycle to address a large patient population with SUI.